Hudelist Gernot, Wuelfing Pia, Czerwenka Klaus, Knöfler Martin, Haider Sandra, Fink-Retter Anneliese, Gschwantler-Kaulich Daphne, Pfeiler Georg, Kubista Ernst, Singer Christian F
Division of Special Gynecology, Department of OB/GYN, Vienna Medical University, Waehringer Guertel 18-20, 1090, Vienna, Austria.
J Cancer Res Clin Oncol. 2009 Feb;135(2):191-5. doi: 10.1007/s00432-008-0458-3. Epub 2008 Aug 29.
The role of the b-HCG/LH/LH-R system in breast cancer is conflicting. Whereas some reports suggest a protective effect of b-HCG on breast epithelium, vitro studies implicate a role of b-HCG/LH-R in the development and growth of breast tumors.
In order to further investigate a possible involvement of b-HCG/LH-R in breast carcinogenesis, immunofluorescence analyses of b-HCG/LH-R expression was performed on 70 preinvasive and adjacent invasive breast cancer specimen using tissue microarrays (TMAs).
In 37 preinvasive samples available for further analysis, b-HCG/LH-R was found in 8/37 samples (21.6%; weak, intermediate and strong staining in 4/37 (10.8%), 2/37 (5.4%) and 2/37 (5.4%). In contrast, b-HCG/LH-R expression was observed in 19/27 (70.4%) adjacent invasive specimen with weak, moderate and strong immunostaining in 10/27 (37.0%), 6/27 (22.2%) and 3/27 (11.1%), respectively. This was statistically significant when compared to preinvasive components (P = 0.001, Chi Square Test).
Based on the observation that b-HCG/LH-R was found to be selectively upregulated in invasive tumor components, we suggest that under certain circumstances, sensitivity of ductal cells to hormones that target b-HCG/LH-R could favour mammary carcinogenesis.
β-人绒毛膜促性腺激素/促黄体生成素/促黄体生成素受体(β-HCG/LH/LH-R)系统在乳腺癌中的作用存在争议。一些报告表明β-HCG对乳腺上皮有保护作用,而体外研究则暗示β-HCG/LH-R在乳腺肿瘤的发生和生长中起作用。
为了进一步研究β-HCG/LH-R在乳腺癌发生中的可能作用,使用组织微阵列(TMA)对70例乳腺原位癌及相邻浸润性癌标本进行了β-HCG/LH-R表达的免疫荧光分析。
在37例可用于进一步分析的原位癌样本中,37例中有8例(21.6%)检测到β-HCG/LH-R(弱阳性、中度阳性和强阳性染色分别为4/37(10.8%)、2/37(5.4%)和2/37(5.4%))。相比之下,在27例相邻浸润性癌标本中有19例(70.4%)观察到β-HCG/LH-R表达,弱阳性、中度阳性和强阳性免疫染色分别为10/27(37.0%)、6/27(22.2%)和3/27(11.1%)。与原位癌成分相比,差异有统计学意义(P = 0.001,卡方检验)。
基于在浸润性肿瘤成分中发现β-HCG/LH-R选择性上调的观察结果,我们认为在某些情况下,导管细胞对靶向β-HCG/LH-R的激素的敏感性可能有利于乳腺癌的发生。